Chaim Charytan

Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial

Brad H. Rovin, Jonathan Barratt, Hiddo J.L. Heerspink et al. · The Lancet · 2023 · 224 citations · Full text

Sparsentan in patients with IgA nephropathy: a prespecified interim analysis from a randomised, double-blind, active-controlled clinical trial

Hiddo J.L. Heerspink, Jai Radhakrishnan, Charles E. Alpers et al. · The Lancet · 2023 · 203 citations · Full text

Glomerulonephritis, Active-controlled Clinical Trial, Renal Function +9

Cinacalcet HCl and Concurrent Low-dose Vitamin D Improves Treatment of Secondary Hyperparathyroidism in Dialysis Patients Compared with Vitamin D Alone

Steven Fishbane, Warren Shapiro, Dalila B. Corry et al. · Clinical Journal of the American Society of Nephrology · 2008 · 169 citations · Full text

Treatment of malnutrition with 1.1% amino acid peritoneal dialysis solution: Results of a multicenter outpatient study

Michael Jones, T Hagen, CA Boyle et al. · American Journal of Kidney Diseases · 1998 · 165 citations

Nutrition, Hemodialysis, Urology +9

Cinacalcet Hydrochloride Is an Effective Treatment for Secondary Hyperparathyroidism in Patients With CKD Not Receiving Dialysis

Chaim Charytan, Jack W. Coburn, Michel Chonchol et al. · American Journal of Kidney Diseases · 2005 · 150 citations

Cinacalcet Hydrochloride, Secondary Hyperparathyroidism, Renal Function +10